Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




New Guidelines for Xenotransplantation

By HospiMedica staff writers
Posted on 21 Dec 2000
Although transplants of hearts or lungs from pigs should not be permitted at the present time, clinical trials of such transplants would be justified when researchers achieve acceptable results in animal studies and have determined there is little risk of spreading animal viruses to humans. More...
This is one of a number of recent recommendations made by a group of leading scientists, doctors, and surgeons assembled by the International Society for Heart and Lung Transplantation (ISHLT) to review the status of cross-species transplantation and its potential for treating patients with end-stage heart and lung diseases. Their review is published in the December issue of Journal of Heart and Lung Transplantation.

The pig is considered to have the best potential as a donor, say the authors, but because of its genetic differences to humans, researchers must devise strategies to overcome the rejection of pig organs. Rejection and other hurdles must be overcome before testing can be permitted to evaluate xenotransplantation in patients. Several strategies show promise, such as humanizing pig organs by introducing certain human proteins into the pig.

Lung transplantation using a pig organ is far from becoming a reality. Continued advancements, however, could make pig-to-human heart transplants feasible within a few years, note the authors. The authors recommend that laboratory evidence would need to indicate that the transplanted pig heart could support a good quality of life for at least six months. This would need to be achieved in the absence of complications from the immunosuppressive drugs required to control rejection. The longest a nonhuman primate has survived supported by a pig heart has been 39 days.

Patients considered for an initial clinical trial should be those who are either currently excluded from receiving a human heart or are unlikely to survive the wait for a human heart and cannot qualify for mechanical heart support.

All xenotransplant trials should be regulated by national bodies that have far-reaching government-backed control, including the authority to halt them if deemed necessary. An international body, such as the ISHLT, should monitor the trials and serve as a registry of information and data.



Related Links:
ISHLT

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Cardiograph Device
PageWriter TC35
Newborn Hearing Screener
ALGO 7i
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.